



Telomeres revisited: *RTEL1* variants in pulmonary fibrosis



Jonathan A. Kropski and James E. Loyd

Affiliation: Division of Allergy, Pulmonary and Critical Care Medicine, Dept of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

Correspondence: Jonathan A. Kropski, 1611 21st Avenue South, T 1218 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. E-mail: Jon.Kropski@vanderbilt.edu



@ERSpublications

Mutations in the telomere pathway gene *RTEL1* represent an important cause of familial pulmonary fibrosis <http://ow.ly/OahXy>

For decades, it has been recognised that cases of pulmonary fibrosis cluster in families. While previous studies have implicated mutations in several surfactant-related proteins [1–3] and telomere-related genes [4–12], in most families the genetic basis of their disease has remained uncertain [13]. In this issue of the *European Respiratory Journal*, KANNENGISSER *et al.* [14] report that rare genetic variants in regulator of telomere elongation helicase 1 (*RTEL1*) are associated with familial pulmonary fibrosis (FPF). Coupled with two other recent reports [7, 10], this work suggests that mutations in *RTEL1* represent an important genetic cause of pulmonary fibrosis, responsible for disease in approximately 6% of families.

The authors selected 35 families from their registry of more than 170 kindreds without known telomerase reverse transcriptase (*TERT*) or telomerase RNA component (*TERC*) mutations and performed whole exome sequencing of genomic DNA from one or two affected individuals. Given the small size of families and limited number of subjects sequenced, standard statistical association testing was not feasible; thus the authors prioritised rare (minor allele frequency <0.01) genetic variants in genes related to telomere biology. As anticipated, no variants in *TERT* or *TERC* were identified; in addition, the authors did not identify rare variants in other FPF-associated telomere genes such as TRF1-interacting nuclear protein 2 (*TINF2*) [5, 8, 12] or dyskerin (*DKC1*) [4, 9]. In four families, rare variants in *RTEL1* were identified, including three missense and one nonsense mutation. The identified *RTEL1* variants segregated with disease within each family and were associated with short peripheral blood telomeres. The authors then used structural modelling techniques that suggested that two of the missense variants in the helicase domain are likely to disrupt DNA binding (R213W) or ATP hydrolysis (T49M); the impact of F964L, which lies in a harmonin-N domain, was less certain but may alter protein folding.

As indicated by the authors, the small size of each kindred suggests that there are probably many other rare variants shared between affected individuals in each family. In addition, functional testing of these *RTEL1* variants will be required to strengthen evidence of pathogenicity. Nonetheless, in light of the strong relationship between telomere biology and lung fibrosis, genetic variation in *RTEL1* appears to be another important contributor to risk for pulmonary fibrosis.

The biology of *RTEL1* is only beginning to be elucidated; however, it is apparent that *RTEL1* plays a role in a variety of fundamental cellular mechanisms related to genome stability, replication and repair [15]. Common genetic variants in *RTEL1* have been associated with peripheral blood telomere length [16] and risk for glioma [17] by genome-wide association studies. Homozygous and/or compound heterozygous *RTEL1* mutations were first identified in Hoyeraal–Hreidarsson syndrome [18–22], including F964L.

Received: May 6 2015 | Accepted: May 11 2015

Support statement: Funding was received from the US Dept of Health and Human Services, National Institutes of Health (grants HL094296 and HL92870). Funding information for this article has been deposited with FundRef.

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Copyright ©ERS 2015

FPF-associated *RTEL1* variants localise to both the helicase domain, critical for T-loop disassembly, as well as the C-terminus, where a harmonin-N domain and PCNA (proliferating cell nuclear antigen)-interacting region are found.

The fundamental mechanism underlying the pathogenesis of lung fibrosis caused by telomere pathway mutations has so far remained elusive. It has commonly been suggested that progressive telomere shortening in type 2 alveolar epithelial cells (AECs) induces premature senescence and loss of regenerative capacity; however, direct evidence for this hypothesis is limited. The lifespan and turnover of type 2 AECs in humans is not known. Lineage tracing models in mice suggest that turnover of the alveolar epithelium occurs slowly (in comparison with the skin or gut epithelium) [23]; thus, gradual telomere shortening through rounds of successive cell division in AECs seems insufficient to explain the profound telomere shortening found in the lungs in idiopathic pulmonary fibrosis, or why a pulmonary phenotype is frequently the first manifestation of telomere pathway mutations. Modelling telomerase mutations in animals has proved challenging, as even late-generation *Tert* and *Terc* null mice fail to recapitulate the lung phenotype associated with human telomere pathway mutations [24, 25]. Activation of a DNA damage response in the alveolar epithelium by inducible deletion of a shelterin complex component (telomere-repeat binding factor-2 (*Trf2*)) led to impaired AEC proliferation, differentiation, and increased sensitivity to bleomycin [26]. While intriguing, the direct relevance of this model to heterozygous human telomere pathway mutations is not entirely clear. Nonetheless, it is apparent that there is an important relationship between telomere biology and lung fibrosis; further study of *RTEL1* and other FPF-associated telomere pathway genes may shed new light on this question.

The authors report numerous extrapulmonary phenotypes, including skeletal abnormalities, liver disease and haematopoietic abnormalities. Liver disease was also identified in another FPF kindred carrying an *RTEL1* rare variant [10]. Bone marrow dyscrasias, skeletal abnormalities and cirrhosis have previously been observed in families with dyskeratosis congenita caused by other telomere pathway mutations [27, 28]. Interestingly, a common genetic variant in *RTEL1* was also recently identified as a susceptibility locus for osteoporosis [29].

With a growing understanding of the genetic basis of FPF, numerous critical questions are emerging that we propose will require broad collaboration within the pulmonary fibrosis community to answer:

- 1) Do patients with *RTEL1* variants have similar clinical courses to other FPF patients? KANNENGISSER *et al.* [14] indicate that disease onset may be earlier than in other FPF patients, although other reports suggest a pattern similar to FPF in general [7, 10].
- 2) Do patients with *RTEL1* and/or telomerase pathway variants respond to idiopathic pulmonary fibrosis treatments, including pirfenidone and nintedanib? The role of genetic predictors of therapeutic response has been virtually unexplored to date.
- 3) Is lung transplantation safe in patients with *RTEL1* mutations? Several reports have suggested that *TERT* mutation carriers are at increased risk for a variety of transplant-related complications, including myelosuppression and renal failure [30, 31]. Similar challenges may be encountered in patients with *RTEL1* variants.
- 4) With evidence of pleiotropic pulmonary and extrapulmonary presentations of FPF-associated genetic variants, what are the critical determinants of the clinical phenotype in an individual? It seems likely that additional genetic or environmental “second hits” are required. Answering this question will require thoughtful epidemiological study in addition to *in vitro* and *in vivo* modelling.
- 5) Should peripheral blood telomere length testing be performed routinely in patients with FPF? Peripheral blood mononuclear cell telomere length may carry prognostic significance [32], and could influence decisions regarding genetic testing.
- 6) Should genetic testing for FPF-associated variants become routine? As it becomes clearer whether specific genetic variants confer prognostic or therapeutically relevant importance, we suggest this should be performed in coordination with genetic counsellors [13].
- 7) Should family members of patients with known FPF-associated genetic variants undergo routine screening for lung disease? In our experience, 15–25% of asymptomatic family members aged ≥ 50 years have evidence of interstitial changes on high-resolution computed tomography scan [33]. With the emergence of effective treatments for disease, a strong case for early disease detection can be made.

In summary, the evolving genetic evidence continues to implicate telomere biology as central to the risk of pulmonary fibrosis. While many more questions lie ahead, identification of *RTEL1* as a pulmonary fibrosis gene provides another important piece of the puzzle of FPF genetics.

References

- 1 Epaud R, Delestrain C, Louha M, *et al.* Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. *Eur Respir J* 2014; 43: 638–641.
- 2 Thomas AQ, Lane K, Phillips J 3rd, *et al.* Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. *Am J Respir Crit Care Med* 2002; 165: 1322–1328.
- 3 Wang Y, Kuan PJ, Xing C, *et al.* Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *Am J Hum Genet* 2009; 84: 52–59.
- 4 Alder JK, Parry EM, Yegnasubramanian S, *et al.* Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. *Hum Mutat* 2013; 34: 1481–1485.
- 5 Alder JK, Stanley SE, Wagner CL, *et al.* Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. *Chest* 2015; 147: 1361–1368.
- 6 Armanios MY, Chen JJ, Cogan JD, *et al.* Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med* 2007; 356: 1317–1326.
- 7 Cogan JD, Kropski JA, Zhao M, *et al.* Rare variants in RTEL1 are associated with familial interstitial pneumonia. *Am J Respir Crit Care Med* 2015; 191: 646–655.
- 8 Fukuhara A, Tanino Y, Ishii T, *et al.* Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. *Eur Respir J* 2013; 42: 1757–1759.
- 9 Kropski JA, Mitchell DB, Markin C, *et al.* A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. *Chest* 2014; 146: e1–e7.
- 10 Stuart BD, Choi J, Zaidi S, *et al.* Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nat Genet* 2015; 47: 512–517.
- 11 Tsakiri KD, Cronkhite JT, Kuan PJ, *et al.* Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proc Natl Acad Sci USA* 2007; 104: 7552–7557.
- 12 Kannengiesser C, Borie R, Revy P. Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? *Eur Respir J* 2014; 44: 269–270.
- 13 Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. *Eur Respir J* 2015; 45: 1717–1727.
- 14 Kannengiesser C, Borie R, Ménard C, *et al.* Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. *Eur Respir J* 2015; 46: 474–485.
- 15 Vannier JB, Sarek G, Boulton SJ. RTEL1: functions of a disease-associated helicase. *Trends Cell Biol* 2014; 24: 416–425.
- 16 Codd V, Nelson CP, Albrecht E, *et al.* Identification of seven loci affecting mean telomere length and their association with disease. *Nat Genet* 2013; 45: 422–427.
- 17 Wrensch M, Jenkins RB, Chang JS, *et al.* Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. *Nat Genet* 2009; 41: 905–908.
- 18 Ballew BJ, Joseph V, De S, *et al.* A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal-Hreidarsson syndrome. *PLoS Genet* 2013; 9: e1003695.
- 19 Ballew BJ, Yeager M, Jacobs K, *et al.* Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. *Hum Genet* 2013; 132: 473–480.
- 20 Deng Z, Glousker G, Molczan A, *et al.* Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome. *Proc Natl Acad Sci USA* 2013; 110: E3408–E3416.
- 21 Le Guen T, Jullien L, Touzot F, *et al.* Human RTEL1 deficiency causes Hoyeraal-Hreidarsson syndrome with short telomeres and genome instability. *Hum Mol Genet* 2013; 22: 3239–3249.
- 22 Walne AJ, Vulliamy T, Kirwan M, *et al.* Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. *Am J Hum Genet* 2013; 92: 448–453.
- 23 Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. *Nature* 2014; 507: 190–194.
- 24 Degryse AL, Xu XC, Newman JL, *et al.* Telomerase deficiency does not alter bleomycin-induced fibrosis in mice. *Exp Lung Res* 2012; 38: 124–134.
- 25 Liu T, Chung MJ, Ullenbruch M, *et al.* Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. *J Clin Invest* 2007; 117: 3800–3809.
- 26 Alder JK, Barkauskas CE, Limjunyawong N, *et al.* Telomere dysfunction causes alveolar stem cell failure. *Proc Natl Acad Sci USA* 2015; 112: 5099–5104.
- 27 Armanios M, Blackburn EH. The telomere syndromes. *Nat Rev Genet* 2012; 13: 693–704.
- 28 Balakumaran A, Mishra PJ, Pawelczyk E, *et al.* Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. *Blood* 2015; 125: 793–802.
- 29 Denny JC, Bastarache L, Ritchie MD, *et al.* Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nat Biotechnol* 2013; 31: 1102–1110.
- 30 Borie R, Kannengiesser C, Hirschi S, *et al.* Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. *J Heart Lung Transplant* 2015; 34: 538–546.
- 31 Silhan LL, Shah PD, Chambers DC, *et al.* Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. *Eur Respir J* 2014; 44: 178–187.
- 32 Stuart BD, Lee JS, Kozlitina J, *et al.* Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. *Lancet Respir Med* 2014; 2: 557–565.
- 33 Kropski JA, Pritchett JM, Zoz DF, *et al.* Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. *Am J Respir Crit Care Med* 2015; 191: 417–426.